Abcellera Biologics Inc (ABCL) support and resistance · rev $12.4M
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
This page maps Abcellera Biologics Inc (ABCL) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported ABCL revenue for 2026-06-30 was $12.4M. Net income was -$98.6M. Revenue was up 48.7% from 2026-03-31 to 2026-06-30. ABCL currently screens at market cap $1.12B.
ABCL currently screens at market cap $1.12B. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new ABCL 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the ABCL quote page for the session range and the stock page for the full model.
Not investment advice.